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Introduction {#sec001}
============

The contactin-associated protein-like 2 (*CNTNAP2*) is located on chromosome 7q35-36.1, and consists of 24 exons spanning 2.3Mb, making it one of the largest protein coding genes in the human genome. This gene encodes the CASPR2 protein, related to the neurexin superfamily, which localises with potassium channels at the juxtaparanodal regions of the Ravier nodes in myelinated axons, playing a crucial role in the clustering of potassium channels required for conduction of axon potentials \[[@pgen.1007535.ref001]\]. *CNTNAP2* is expressed in the spinal cord, prefrontal and frontal cortex, striatum, thalamus and amygdala; this pattern of expression is preserved throughout the development and adulthood \[[@pgen.1007535.ref002], [@pgen.1007535.ref003]\]. Its function is related to neuronal migration, dendritic arborisation and synaptic transmission \[[@pgen.1007535.ref004]\]. The crucial role of *CNTNAP2* in the human brain became clear in 2006 when Strauss *et al*, reported homozygous mutations in Old Order Amish families segregating with a severe Mendelian condition, described as cortical dysplasia-focal epilepsy (CDFE) syndrome (OMIM 610042) \[[@pgen.1007535.ref005]\]. In 2009, additional patients with recessive mutations in *CNTNAP2* were reported, with clinical features resembling Pitt-Hopkins syndrome \[[@pgen.1007535.ref006]\]. To date 33 patients, mostly from consanguineous families, have been reported with homozygous or compound deletions and truncating mutations in *CNTNAP2* \[[@pgen.1007535.ref005]--[@pgen.1007535.ref009]\], and are collectively described as having CASPR2 deficiency disorder \[[@pgen.1007535.ref007]\]. The common clinical features in this phenotype include severe intellectual disability (ID), seizures with age of onset at two years and concomitant speech impairments or language regression. The phenotype is often accompanied by dysmorphic features, autistic traits, psychomotor delay and focal cortical dysplasia.

*CNTNAP2* is also thought to contribute to diverse phenotypes in patients with interstitial or terminal deletions at 7q35 and 7q36. Interstitial or terminal deletions encompassing *CNTNAP2* and several other genes have been described in individuals with ID, seizures, craniofacial anomalies, including microcephaly, short stature and absence of language \[[@pgen.1007535.ref010]\]. The severe language impairments observed in patients with homozygous mutations or karyotypic abnormalities involving *CNTNAP2* suggested a possible functional interaction with *FOXP2*, a gene for which heterozygous mutations lead to a monogenic form of language disorder \[[@pgen.1007535.ref011]\]. Interestingly, *Vernes et al*., found that the FOXP2 transcription factor has a binding site in intron 1 of *CNTNAP2*, regulating its expression \[[@pgen.1007535.ref012]\]. Considering that a large proportion of autistic patients show language impairments and most individuals with homozygous mutations in *CNTNAP2* manifest autistic features, several studies investigated the potential involvement of *CNTNAP2* in autism spectrum disorder (ASD). In particular, two pioneering studies showed that single nucleotide polymorphism (SNP) markers rs2710102 and rs7794745 were associated with risk of ASD \[[@pgen.1007535.ref013], [@pgen.1007535.ref014]\]. These studies were the first implicating *CNTNAP2* in autism, and opened a chapter of additional analyses in ASD and other psychiatric phenotypes during the next decade. In subsequent studies, rs2710102 was implicated in early language acquisition in the general population \[[@pgen.1007535.ref015]\], and showed functional effects on brain activation in neuroimaging studies \[[@pgen.1007535.ref016]--[@pgen.1007535.ref019]\]. Furthermore, genotypes at rs7794745 were associated with reduced grey matter volume in the left superior occipital gyrus in two independent studies \[[@pgen.1007535.ref020], [@pgen.1007535.ref021]\], and alleles of this SNP were reported to affect voice-specific brain function \[[@pgen.1007535.ref022]\]. Genetic associations with ASD for these, and several other SNPs in *CNTNAP2*, have been reported in a number of studies \[[@pgen.1007535.ref023]--[@pgen.1007535.ref028]\]. Along with the first reports of SNPs associated with ASD, copy number variant (CNV) deletions have also been described in ID or ASD patients, which were proposed to be highly penetrant disease-causative mutations \[[@pgen.1007535.ref013], [@pgen.1007535.ref029]--[@pgen.1007535.ref038]\]. To better understand the role of *CNTNAP2* in ASD pathophysiology, knockout mice were generated. Studies of these mice reported several neuronal defects when both copies of *CNTNAP2* are mutated: abnormal neuronal migration, reduction of GABAergic interneurons, deficiency in excitatory neurotransmission, and the delay of myelination in the neocortex \[[@pgen.1007535.ref002], [@pgen.1007535.ref039], [@pgen.1007535.ref040]\].

These intriguing findings prompted additional investigations of *CNTNAP2* across other psychiatric disorders or language-related traits, with additional reports of SNPs being associated with schizophrenia (SCZ), bipolar disorder (BD), specific language impairment (SLI) and several other phenotypes or traits \[[@pgen.1007535.ref012], [@pgen.1007535.ref015], [@pgen.1007535.ref041]--[@pgen.1007535.ref050]\]. Consequently, other studies reported CNV deletions in *CNTNAP2* in schizophrenia \[[@pgen.1007535.ref051], [@pgen.1007535.ref052]\], bipolar disorder \[[@pgen.1007535.ref052]--[@pgen.1007535.ref054]\], and ADHD \[[@pgen.1007535.ref055]\]; but also in neurological disorders, especially epilepsy \[[@pgen.1007535.ref056]--[@pgen.1007535.ref061]\], and language-related phenotypes \[[@pgen.1007535.ref062]--[@pgen.1007535.ref065]\]. Interestingly, several of these structural variants were found in intron 1 of *CNTNAP2*, encompassing the FOXP2 transcription factor binding site. Epilepsy is clinically frequent in psychiatric disorders, especially schizophrenia and bipolar disorder \[[@pgen.1007535.ref066]--[@pgen.1007535.ref069]\], and is present in approximately 20% of autistic patients \[[@pgen.1007535.ref070], [@pgen.1007535.ref071]\]. Similarly, cognitive deficits involving language-related domains are also comorbid traits in schizophrenia and bipolar disorder \[[@pgen.1007535.ref067], [@pgen.1007535.ref072]--[@pgen.1007535.ref074]\], and are common clinical features in ASD \[[@pgen.1007535.ref075]\], with many ASD patients remaining non-verbal throughout life \[[@pgen.1007535.ref075], [@pgen.1007535.ref076]\].

While *CNTNAP2* is now considered a strong candidate gene for ASD and psychiatric disease more generally (summarised in [Table 1](#pgen.1007535.t001){ref-type="table"}), several of these early supportive studies were performed with limited sample sizes, or were individual case reports which lacked comparison with control individuals, hence providing circumstantial evidence as a psychiatric risk gene. We therefore aimed in this current study to perform systematic genetic analyses with large datasets to examine the evidence for a role of the *CNTNAP2* gene in multiple psychiatric phenotypes--performing a comprehensive analysis of common and rare variants, CNVs and *de novo* mutations--using both publicly available datasets and in-house data.

10.1371/journal.pgen.1007535.t001

###### Overview of studies implicating common alleles, structural variants or rare variants of *CNTNAP2* in psychiatric disorders.
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  Psychiatric phenotype                      Variant described           Reference
  ------------------------------------------ --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Autism Spectrum Disorder                   Associated SNP              Alarcon et al., 2008 \[[@pgen.1007535.ref013]\]; Arking et al., 2008 \[[@pgen.1007535.ref014]\]; Steer et al., 2010 \[[@pgen.1007535.ref023]\]; Anney et al., 2012 \[[@pgen.1007535.ref027]\]; Sampath et al., 2013 \[[@pgen.1007535.ref026]\]; Poot, 2014 \[[@pgen.1007535.ref028]\]; Chiocchetti et al., 2015 \[[@pgen.1007535.ref025]\]; Nascimento et al., 2016 \[[@pgen.1007535.ref024]\].
                                             CNV deletion                Alarcon et al., 2008 \[[@pgen.1007535.ref013]\]; Poot et al., 2010 \[[@pgen.1007535.ref034]\]; Nord et al., 2011 \[[@pgen.1007535.ref037]\]; Girirajan et al., 2013 \[[@pgen.1007535.ref035]\]; Egger et al., 2014 \[[@pgen.1007535.ref038]\].
                                             CNV duplication             Prasad et al., 2012 \[[@pgen.1007535.ref036]\]; Girirajan et al., 2013 \[[@pgen.1007535.ref035]\].
                                             Rearrangement (Inversion)   Bakkaloglu et al., 2008 \[[@pgen.1007535.ref033]\].
                                             Rare variants               Bakkaloglu et al., 2008 \[[@pgen.1007535.ref033]\]; Chiocchetti et al., 2015 \[[@pgen.1007535.ref025]\].
  Schizophrenia                              Associated SNP              Wang et al., 2010 \[[@pgen.1007535.ref041]\]; Ji et al., 2013 \[[@pgen.1007535.ref049]\]; Chen et al. 2015, \[[@pgen.1007535.ref045]\];
                                             CNV deletion                Malhotra et al., 2011 \[[@pgen.1007535.ref052]\]; Friedman et al., 2008 \[[@pgen.1007535.ref051]\].
  Bipolar Disorder                           Associated SNP              Wang et al., 2010 \[[@pgen.1007535.ref041]\].
                                             CNV deletion                Zhang et al., 2009 \[[@pgen.1007535.ref053]\]; Malhotra et al., 2011 \[[@pgen.1007535.ref052]\]; Lee et al., 2015 \[[@pgen.1007535.ref054]\].
                                             CNV duplication             Malhotra et al., \[[@pgen.1007535.ref052]\].
  Attention Deficit Hyperactivity Disorder   CNV duplication             Elia et al., 2010 \[[@pgen.1007535.ref055]\].
  Major Depressive Disorder                  Associated SNP              Ji et al., 2013 \[[@pgen.1007535.ref049]\]; Wray et al., 2012 \[[@pgen.1007535.ref044]\].
  Alcohol dependence                         Associated SNP              Zhong et al., 2005 \[[@pgen.1007535.ref042]\].

Results {#sec002}
=======

Analysis of *CNTNAP2* common single nucleotide variation in the susceptibility of psychiatric disorders {#sec003}
-------------------------------------------------------------------------------------------------------

During the last decade, several association studies have been performed to assess the role of common variants of *CNTNAP2* in autism or speech-related phenotypes \[[@pgen.1007535.ref012]--[@pgen.1007535.ref015], [@pgen.1007535.ref023]--[@pgen.1007535.ref028], [@pgen.1007535.ref046]--[@pgen.1007535.ref048], [@pgen.1007535.ref050]\], as well as several other psychiatric phenotypes \[[@pgen.1007535.ref041]--[@pgen.1007535.ref045], [@pgen.1007535.ref049]\]. In [Table 2](#pgen.1007535.t002){ref-type="table"}, we summarise all markers found significantly associated in these previous studies, and report the corresponding *P-value* from the Psychiatric Genomics Consortium GWAS for seven major psychiatric disorders: ADHD, anorexia nervosa, ASD, bipolar disorder, MDD, OCD and schizophrenia. Nominal associations were found with ASD for the following markers: rs802524 (*P* = 0.016), rs802568 (*P* = 0.008), rs17170073 (*P* = 0.008), and rs2710102 (*P* = 0.036; which is highly correlated with 4 SNPs: rs759178, rs1922892, rs2538991, rs2538976). Furthermore, nominal association was also observed with schizophrenia for rs1859547 (*P* = 0.044); with ADHD for rs1718101 (*P* = 0.038); with MDD for rs12670868 (*P* = 0.047), rs17236239 (*P* = 0.006), rs4431523 (*P* = 0.001); and with anorexia nervosa for rs700273 (*P* = 0.013). The nominal association with ASD at rs1770073 and rs2710102 represents the only case in which the association in the original report replicates in the PGC dataset for the same phenotype. The two SNPs rs7794745 and rs2710102, which were repeatedly reported as being associated in earlier studies with smaller sample size and proposed to be functional SNPs, were not strongly associated with any phenotype (the most significant signal being *P* = 0.036 for rs2710102 in ASD). None of those associations survived corrections for multiple comparisons ([Table 2](#pgen.1007535.t002){ref-type="table"}).

10.1371/journal.pgen.1007535.t002

###### Common SNPs in *CNTNAP2* previously reported to be associated in psychiatric diseases, and their evidence for association in PGC datasets.
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                                                                                                                                                                                                                                                                      PGC Association Results (*P-Value*)                                                                                     
  ----------------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ ----------- --------- ----------- ------------------------ ----------- --------
  rs34712024                                                        Promoter    ASD \[[@pgen.1007535.ref025]\]                                                                                                                                                        0.672[\^](#t002fn004){ref-type="table-fn"}       0.45        0.099     0.442       N/A                      0.283       0.295
  rs802524                                                          Intron 1    SCZ, BD \[[@pgen.1007535.ref041]\]                                                                                                                                                    **0.016**[\^](#t002fn004){ref-type="table-fn"}   0.081       0.058     0.210       0.070                    0.143       0.039
  rs802568                                                          Intron 1    SCZ, BD \[[@pgen.1007535.ref041]\]                                                                                                                                                    **0.008**[\^](#t002fn004){ref-type="table-fn"}   0.061       0.312     0.047       0.054                    0.321       0.279
  rs17170073                                                        Intron 1    ASD \[[@pgen.1007535.ref026]\]                                                                                                                                                        **0.008**                                        0.903       0.558     0.883       0.306                    0.031       0.101
  rs1718101                                                         Intron 1    ASD \[[@pgen.1007535.ref027]\]                                                                                                                                                        0.076[\^](#t002fn004){ref-type="table-fn"}       0.257       0.215     **0.038**   0.255                    0.243       0.029
  rs700273                                                          Intron 1    ALD \[[@pgen.1007535.ref042]\]                                                                                                                                                        0.840                                            0.655       0.837     0.544       0.338                    **0.013**   0.554
  [*rs7794745*]{.ul}                                                Intron 2    ASD \[[@pgen.1007535.ref014], [@pgen.1007535.ref023], [@pgen.1007535.ref024]\]                                                                                                        0.906                                            0.734       0.498     0.393       0.173                    0.877       0.503
  rs10251794                                                        Intron 3    OPN \[[@pgen.1007535.ref043]\]                                                                                                                                                        0.301                                            0.365       0.155     0.452       **0.047** (rs12670868)   0.648       0.351
  rs7804520                                                         Intron 3    ASD \[[@pgen.1007535.ref028]\]                                                                                                                                                        0.378                                            0.277       0.236     0.155       0.568                    0.506       0.682
  rs1603450                                                         Intron 8    LAN \[[@pgen.1007535.ref015]\]                                                                                                                                                        0.445                                            0.166       0.643     0.141       0.010                    0.951       0.577
  rs826824                                                          Intron 9    MDD (male only) \[[@pgen.1007535.ref044]\]                                                                                                                                            0.218                                            0.181       0.256     0.317       0.266                    0.736       0.199
  rs1859547                                                         Intron 11   SCZ \[[@pgen.1007535.ref045]\]                                                                                                                                                        0.697                                            **0.044**   0.431     0.225       0.939                    0.729       0.154
  rs851715[^**&**^](#t002fn002){ref-type="table-fn"}                Intron 13   SLI \[[@pgen.1007535.ref012]\]                                                                                                                                                        0.448                                            0.496       0.572     0.067       0.601                    0.920       0.411
  rs10246256[^**&**^](#t002fn002){ref-type="table-fn"}              Intron 13   SLI \[[@pgen.1007535.ref012], [@pgen.1007535.ref046]\]                                                                                                                                0.429                                            0.613       0.508     0.070       0.601 (rs851715)         0.871       0.454
  [*rs2710102*]{.ul}[^***\#***^](#t002fn003){ref-type="table-fn"}   Intron 13   ASD, SLI, DYS, SM, ANX, LAN, MDD \[[@pgen.1007535.ref012], [@pgen.1007535.ref013], [@pgen.1007535.ref015], [@pgen.1007535.ref023], [@pgen.1007535.ref046]--[@pgen.1007535.ref049]\]   **0.036**                                        0.893       0.801     0.911       0.346                    0.383       0.351
  rs759178[^***\#***^](#t002fn003){ref-type="table-fn"}             Intron 13   SLI, LAN \[[@pgen.1007535.ref012], [@pgen.1007535.ref015]\]                                                                                                                           **0.037**                                        0.890       0.799     0.929       0.332                    0.363       0.347
  rs1922892[^***\#***^](#t002fn003){ref-type="table-fn"}            Intron 13   SLI \[[@pgen.1007535.ref012]\]                                                                                                                                                        **0.039**                                        0.908       0.794     0.940       0.332 (rs759178)         0.359       0.346
  rs2538991[^***\#***^](#t002fn003){ref-type="table-fn"}            Intron 13   SLI \[[@pgen.1007535.ref012]\]                                                                                                                                                        **0.041**                                        0.852       0.797     0.989       0.332 (rs759178)         0.366       0.338
  rs17236239                                                        Intron 13   ASD, SCZ, SLI \[[@pgen.1007535.ref012], [@pgen.1007535.ref023], [@pgen.1007535.ref027], [@pgen.1007535.ref046], [@pgen.1007535.ref049]\]                                              0.142                                            0.290       0.278     0.883       **0.006**                0.622       0.954
  rs2538976[^***\#***^](#t002fn003){ref-type="table-fn"}            Intron 13   SLI, SSD \[[@pgen.1007535.ref012], [@pgen.1007535.ref050]\]                                                                                                                           0.051                                            0.718       0.692     0.812       0.358                    0.408       0.424
  rs2215798                                                         Intron 13   ASD \[[@pgen.1007535.ref026]\]                                                                                                                                                        0.5                                              0.469       0.361     0.742       0.030                    0.568       0.281
  rs4431523                                                         Intron 13   SLI \[[@pgen.1007535.ref012]\]                                                                                                                                                        0.275                                            0.844       0.676     0.614       **0.001** (rs2708267)    0.933       0.972
  rs2710117                                                         Intron 14   SLI, MDD \[[@pgen.1007535.ref012], [@pgen.1007535.ref046], [@pgen.1007535.ref049]\]                                                                                                   0.1477                                           0.6701      0.7566    0.2106      0.894 (rs2710121)        0.993       0.321
  rs2710093                                                         Intron 14   ASD \[[@pgen.1007535.ref026]\]                                                                                                                                                        0.4077                                           0.2891      0.02819   0.2943      0.090 (rs2710091)        0.8416      0.2767

The disease for which association at each listed SNP is given, along with the reference number for each study and the approximate location of each variant within the *CNTNAP2* gene structure. On the right, the *P-value* from each Psychiatric Genomics Consortium (PGC) dataset is reported. Where the associated SNP was not found in the GWAS summary statistic data, results for an alternative SNP are shown in parenthesis (r^2^ = 1). Putative functional SNPs rs7794745 and rs2710102 are underlined. No association survives correction for multiple independent tests (*P* \<3.8E-04), but *P-values* \< 0.05 are shown in bold. Abbreviations: ASD, autism spectrum disorder; SLI, specific language impairment; DYS, dyslexia; ANX, social anxiety; LAN, language in general population; SCZ, schizophrenia; BD, bipolar disorder; ALD, Alcohol dependence; OPN, Openness general population; MDD, major depressive disorder; SSD, speech sound disorder; N/A, SNP not genotyped

&, r^2^\>0.97 across the following SNPs: rs851715 and rs10246256

\#, r^2^\>0.97 across the following SNPs: rs2710102, rs759178, rs1922892, rs2538991 and rs2538976

\^, summary data at this SNP was not included in the latest autism GWAS (PGC2) but was present in the previous data set which included 5,305 ASD cases and 5,305 controls.

Gene-based analysis of cross-disorder associations {#sec004}
--------------------------------------------------

Next, we explored the contribution of common variants across *CNTNAP2* by performing a gene-based association study in MAGMA using GWAS summary statistics from PGC data of seven psychiatric disorders in European populations ([Table 3](#pgen.1007535.t003){ref-type="table"}). Association plots for all SNPs included in analysis of each individual phenotype are shown in supporting information ([S1 Fig](#pgen.1007535.s001){ref-type="supplementary-material"}).

10.1371/journal.pgen.1007535.t003

###### Gene-based tests for association of *CNTNAP2* across seven psychiatric disorders using GWAS summary statistics of the PGC data sets.
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  Disease                                      N Cases--Controls   N SNPs tested   Gene-based *P-value*   Top SNP       Top SNP *P-value*
  -------------------------------------------- ------------------- --------------- ---------------------- ------------- -------------------
  ADHD[^a^](#t003fn002){ref-type="table-fn"}   19,099--34,194      7,538           0.16                   rs370840971   4.8E-04
  AN[^a^](#t003fn002){ref-type="table-fn"}     3,495--10,982       9,318           0.33                   rs138287908   8.5E-05
  ASD[^a^](#t003fn002){ref-type="table-fn"}    6,197--7,377        5,946           0.54                   rs1089600     0.0018
  BD[^a^](#t003fn002){ref-type="table-fn"}     20,352--31,358      11,345          0.34                   rs181471483   3.6E-04
  MDD[^b^](#t003fn003){ref-type="table-fn"}    9,240--9,519        1,214           ***0*.*029***          rs4725752     9.3E-04
  OCD[^a^](#t003fn002){ref-type="table-fn"}    2,688--7,037        8,631           0.30                   rs6976859     8.7E-05
  SCZ[^a^](#t003fn002){ref-type="table-fn"}    33,640--43,456      12,264          0.11                   rs78093069    1.1E-04

The numbers (N) of cases and controls in each dataset examined are given, along with the number of SNPs tested in each dataset. The name and *P-value* of the SNP with most significant association is given. Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AN, anorexia nervosa; ASD, Autism spectrum disorder; BD, bipolar disorder; MDD, major depressive disorder; OCD, obsessive compulsive disorder; SCZ, schizophrenia

^a^, European individuals from the PGC2 data sets

^b^, European individuals from the PGC1 data sets.

The test included a dense coverage of SNPs across *CNTNAP2*: from 1,214 SNPs in MDD up to 12,264 SNPs in schizophrenia. The results suggest that common variants overall do not contribute to disease susceptibility of these phenotypes ([Table 3](#pgen.1007535.t003){ref-type="table"}). The most significant association observed was for MDD phase 1 analysis (*P* = 0.029), which is the dataset with the most modest coverage of markers.

To explore whether any gene-based signal is not being detected due to a high signal-to-noise ratio (i.e. inclusion of a large number of SNPs of no functional consequence), we selected 63 predicted functional SNPs in *CNTNAP2* and performed a meta-analysis across psychiatric disorders (for regional association plot, see [S2 Fig](#pgen.1007535.s002){ref-type="supplementary-material"}). Nominal significance of association was observed for 11 predicted functional SNPs with *P-values* ranging from 0.01 and 0.05, but none survive correction for multiple comparisons ([Table 4](#pgen.1007535.t004){ref-type="table"}).

10.1371/journal.pgen.1007535.t004

###### Cross psychiatric disorders meta-analysis of 63 predicted functional SNPs.
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  SNPs         Allele   Function            Datasets                           I    *P-val*     OR
  ------------ -------- ------------------- ---------------------------------- ---- ----------- -------
  rs17480644   A/G      TFBS                ADHD, AN, BD, OCD, SCZ             8    0.083       1.039
  rs1260124    A/T      TFBS                ADHD, AN, ASD, BD, OCD, SCZ        0    0.635       0.996
  rs35796336   T/C      TFBS                AN, ASD, BD, OCD, SCZ              0    **0.049**   1.027
  rs10277276   T/C      TFBS                BD, OCD, SCZ                       0    0.764       0.992
  rs34712024   A/G      TFBS                ADHD, AN, BD, OCD, SCZ             32   0.626       1.012
  rs2462603    A/G      TFBS                ADHD, AN, ASD, BD, OCD, SCZ        0    0.303       0.993
  rs1639484    A/T      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.376       1.005
  rs12703814   A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.965       0.999
  rs1639447    A/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.376       0.990
  rs769344     C/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.778       0.996
  rs10280967   A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.639       0.996
  rs10243142   T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.738       1.002
  rs12535047   T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   0    0.327       0.993
  rs347201     A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.089       1.011
  rs13234249   T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   2    0.101       1.011
  rs12666908   T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.914       0.999
  rs11972428   T/G      SeqCons             ADHD, AN, BD, OCD, SCZ             0    0.672       1.012
  rs34222835   A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        4    **0.045**   0.979
  rs10261412   A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   52   0.808       0.995
  rs1826843    A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   20   0.153       0.990
  rs17170356   A/G      SeqCons             ADHD, AN, BD, OCD, SCZ             0    0.137       0.972
  rs4726831    A/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        18   0.294       0.990
  rs10279700   T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   26   0.857       0.998
  rs35701811   A/G      SeqCons             ADHD, AN, BD, OCD, SCZ             0    0.899       0.998
  rs899617     T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    **0.026**   1.014
  rs747140     C/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    **0.025**   1.014
  rs7798078    A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   0    0.091       1.011
  rs34592169   A/G      Splicing            ADHD, AN, ASD, BD, OCD, SCZ        15   0.067       1.014
  rs6970064    A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   7    0.462       1.004
  rs17170640   A/G      SeqCons             ADHD, AN, BD, OCD, SCZ             0    **0.018**   1.041
  rs16883690   A/C      SeqCons             BD, SCZ                            66   0.673       1.066
  rs7797724    T/C      SeqCons             BD, SCZ                            0    **0.047**   1.592
  rs851659     A/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        9    0.349       0.993
  rs35815165   -/AA     SeqCons             ADHD, AN                           0    0.831       1.002
  rs13247212   T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.797       0.996
  rs1177007    A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   0    0.238       1.008
  rs12154883   T/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.645       1.006
  rs13438769   T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   0    0.057       1.018
  rs2707580    T/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.146       0.990
  rs2707581    T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.156       0.990
  rs2141955    A/G      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    **0.032**   1.015
  rs34347668   A/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ        0    0.973       1.000
  rs4725756    A/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   0    **0.015**   0.984
  rs2888540    T/C      SeqCons             ADHD, AN, ASD, BD, OCD, SCZ, MDD   0    **0.023**   1.014
  rs17170789   A/T      SeqCons             ADHD, AN, BD, OCD, SCZ             0    0.566       1.010
  rs17170801   A/C      SeqCons             ADHD, AN, BD, OCD, SCZ             0    0.643       0.989
  rs10279343   T/C      SeqCons             ADHD, AN, BD, OCD, SCZ             1    0.568       1.014
  rs1122622    A/C      SeqCons             AN, BD, OCD, SCZ                   66   0.745       1.026
  rs5888312    -/A      SeqCons             ADHD, AN                           70   0.744       1.010
  rs9648691    A/G      SeqCons, Splicing   ADHD, AN, ASD, BD, OCD, SCZ, MDD   64   0.806       1.002
  rs987456     A/C      miRNA               ADHD, AN, ASD, BD, OCD, SCZ, MDD   29   0.570       1.004
  rs2717809    C/G      miRNA               AN, BD, OCD, SCZ                   0    0.746       0.989
  rs2530312    A/G      miRNA               ADHD, AN, ASD, BD, OCD, SCZ        70   0.485       0.990
  rs3194       A/C      miRNA               ADHD, AN, ASD, BD, OCD, SCZ, MDD   68   0.797       1.003
  rs10243309   C/T      miRNA               AN, MDD                            15   0.125       1.149
  rs17170999   A/G      miRNA               AN, BD, OCD, SCZ, MDD              0    **0.026**   0.917
  rs2530311    A/G      miRNA               ADHD, AN, ASD, BD, OCD, SCZ, MDD   66   0.975       0.999
  rs17171000   T/C      miRNA               ADHD, AN, BD, OCD, SCZ, MDD        0    0.583       0.988
  rs10251347   C/G      miRNA               ADHD, AN, BD, OCD, SCZ, MDD        0    0.428       0.986
  rs2717829    C/G      miRNA               ADHD, AN, ASD, BD, OCD, SCZ, MDD   50   0.820       0.997
  rs10280038   A/G      miRNA               AN, BD, OCD, SCZ, MDD              0    **0.031**   1.087
  rs2530310    T/C      miRNA               ADHD, AN, ASD, BD, OCD, SCZ, MDD   67   0.666       0.994
  rs17171006   T/C      miRNA               ADHD, AN, BD, OCD, SCZ             0    0.493       0.985

For each predicted functional SNP, the alternative alleles and predicted function are listed. *P-values* (*P-val*) were calculated considering fixed-model effect, except SNPs with evidence of heterogeneity (I\>50) where odds ratios (OR) were considered under random-effects. Nominally significant associations are indicated in bold *(P-values\<0*.*05)*, but none exceed correction for multiple testing (*P*\<7.9E-04). Abbreviations: TFBS, transcription factor binding site; SeqCons, sequence conserved nucleotide across species; miRNA, predicted miRNA binding site; Splicing, exonic splicing enhancer (ESE).

The only predicted functional SNP which was previously reported as being associated with ASD was rs34712024 \[[@pgen.1007535.ref025]\], but this variant was not associated with autism in the PGC dataset (*P* = 0.67; [Table 2](#pgen.1007535.t002){ref-type="table"}), nor other psychiatric phenotypes examined separately or together (Tables [2](#pgen.1007535.t002){ref-type="table"}--[4](#pgen.1007535.t004){ref-type="table"}). MAGMA gene-based association analysis using this more restricted pool of common putative functional variants revealed significant association with ADHD after correction for multiple testing (corrected *P-value* = 0.033) and a nominal association with schizophrenia which did not survive multiple testing correction ([S1 Table](#pgen.1007535.s003){ref-type="supplementary-material"}). However, this signal is reduced to trend level in the cross-disorder meta-analysis for this functional SNP-set (*P-value* = 0.11; [S1 Table](#pgen.1007535.s003){ref-type="supplementary-material"}).

*De novo* variants in *CNTNAP2* {#sec005}
-------------------------------

*De novo* variants in protein-coding genes which are predicted to be functionally damaging are considered to be highly pathogenic and have been extensively explored to implicate genes in psychiatric diseases, especially in ASD and schizophrenia \[[@pgen.1007535.ref077]\]. We explored publicly available sequence data from previous projects in psychiatric disorders to assess the rate of coding *de novo* variants in *CNTNAP2* using two databases (NPdenovo, <http://www.wzgenomics.cn/NPdenovo/>; and denovo-db, <http://denovo-db.gs.washington.edu/denovo-db/>). No truncating or missense variants were identified across *CNTNAP2* in 15,539 families (including 2,163 controls), and synonymous variants were reported in only two probands with developmental disorder ([Table 5](#pgen.1007535.t005){ref-type="table"}).

10.1371/journal.pgen.1007535.t005

###### *CNTNAP2 de novo* variants identified across several disease-specific sequencing projects.

![](pgen.1007535.t005){#pgen.1007535.t005g}

  Phenotype   N Families   Intronic   Synonymous   Missense
  ----------- ------------ ---------- ------------ ----------
  ASD         6,171        106        \-           \-
  SCZ         1,164        \-         \-           \-
  EE          647          \-         \-           \-
  ID          1,101        \-         \-           \-
  DD          4,293        \-         2            \-
  Controls    2,163        13         \-           \-

The number (N) of families in each dataset examined is given. The full list of *de novo* variants observed is listed in [S2 Table](#pgen.1007535.s004){ref-type="supplementary-material"}. Abbreviations: ASD, autism spectrum disorder; SCZ, schizophrenia; EE, epilepsy; ID, intellectual disability; DD, developmental disability.

Pathogenic Ultra-Rare Variants (URV) of *CNTNAP2* in ASD and Schizophrenia {#sec006}
--------------------------------------------------------------------------

Finally, we explored the potential impact of pathogenic ultra-rare variants (URV) in *CNTNAP2* using available sequencing datasets of 4,483 patients with ASD and 6,135 patients with schizophrenia compared with 13,042 controls. We considered only those variants predicted to be pathogenic in both SIFT and Polyphen and which are ultra-rare (MAF\<0.0001 in Non-Finnish European population; [S3 Table](#pgen.1007535.s005){ref-type="supplementary-material"}). No difference in the total number of URV was observed between controls and patients with ASD (*P* = 0.11), or schizophrenia (*P* = 0.78) ([Table 6](#pgen.1007535.t006){ref-type="table"}).

10.1371/journal.pgen.1007535.t006

###### Burden analysis of *CNTNAP2* ultra-rare variants (URVs) in ASD and SCZ.

![](pgen.1007535.t006){#pgen.1007535.t006g}

             N Individuals   N Pathogenic URVs   *P-Value*
  ---------- --------------- ------------------- -----------
  Controls   13,042          59                  
  SCZ        6,135           26                  0.78
  ASD        4,483           29                  0.11

The selection of variants included missense variants which are predicted to be pathogenic, truncating variants and canonical splice-site variants. The full list of URVs observed is provided in [S3 Table](#pgen.1007535.s005){ref-type="supplementary-material"}. Abbreviations: SCZ, schizophrenia; ASD, autism spectrum disorder.

Structural variants affecting *CNTNAP2* amongst psychiatric phenotypes {#sec007}
----------------------------------------------------------------------

Several deletions and duplications have been described in neuropsychiatric phenotypes thus far. In [Fig 1](#pgen.1007535.g001){ref-type="fig"}, we present a comprehensive representation of all previously reported structural variants found in *CNTNAP2* in psychiatric disorders such as ASD or ID \[[@pgen.1007535.ref013], [@pgen.1007535.ref029]--[@pgen.1007535.ref038]\], schizophrenia or bipolar disorder \[[@pgen.1007535.ref051]--[@pgen.1007535.ref054], [@pgen.1007535.ref078]\], ADHD \[[@pgen.1007535.ref055]\], neurologic disorders such as epilepsy, Tourette syndrome or Charcot-Marie-Tooth \[[@pgen.1007535.ref056]--[@pgen.1007535.ref061]\]; and finally language-related phenotypes such as speech delay, childhood apraxia of speech and dyslexia \[[@pgen.1007535.ref062]--[@pgen.1007535.ref065]\]. Interestingly, the reported structural variants frequently map in intron 1, and extend to exon 4 in some cases. The distribution of those structural variants across different phenotypes does not vary with those found in control populations from the database of genomic variants (<http://dgv.tcag.ca/dgv/app/home>) ([Fig 1](#pgen.1007535.g001){ref-type="fig"}), suggesting that structural variants in *CNTNAP2* are not rare events associated exclusively to disease but are present with rare frequency in the general population. Unfortunately, as many reported CNVs come from individual case reports for which the number of subjects screened is not reported, direct frequency comparisons of this data are not meaningful.

![Overview of heterozygous CNVs spanning the *CNTNAP2* gene across several diseases.\
Abbreviations: ID (Intellectual disability), ASD (autism spectrum disorder), SCZ (schizophrenia), BD (bipolar disorder), ADHD (Attention-deficit/hyperactivity disorder), EP (epilepsy), TS (Tourette syndrome), CMT2 (axonal Charcot-Marie-Tooth), and SS (Speech spectrum: speech delay, childhood apraxia of speech and dyslexia). In parenthesis is reported the reference to each study. \*, additional rearrangements reported in this patient. The dashed lines represent the exons and the upper box shows the position of the FOXP2 binding site. In dark shading, CNVs≥80kb found in the general populations from the Database of Genomic Variants are shown.](pgen.1007535.g001){#pgen.1007535.g001}

Examination of an intronic deletion in *CNTNAP2* in an extended family with bipolar disorder {#sec008}
--------------------------------------------------------------------------------------------

CNV microarray analysis was previously performed in two affected individuals from an extended family which included five relatives affected with bipolar I disorder \[[@pgen.1007535.ref078]\]. A drop in signal intensity for 340 consecutive probes was compatible with a deletion of 131 kb in intron 1 of *CNTNAP2* (hg19/chr7:146203548--146334635; [Fig 2A](#pgen.1007535.g002){ref-type="fig"}), encompassing the described binding site for the transcription factor FOXP2 (hg19/chr7:146215016--146215040) \[[@pgen.1007535.ref012]\]. The deletion was detected in one of the two affected individuals examined by CNV array. To infer deletion segregation amongst additional relatives, WES-derived genotypes were used to create haplotypes across chromosome 7q35 ([Fig 2B](#pgen.1007535.g002){ref-type="fig"}). CNV segregation (by haplotype inference) was uninformative due to: 1) incomplete genotype data (unaffected descendants of deceased patient 8404 were not included in the WES study) and 2) a likely recombination at 7q35 in the family. Thus experimental validation and CNV genotyping was performed in all individuals with DNA available to assess the presence of the *CNTNAP2* intronic deletion and its disease association. Using quantitative PCR, the deletion was validated in proband subject 8401, and was detected in one unaffected descendant of deceased patient 8404 ([Fig 2B and 2C](#pgen.1007535.g002){ref-type="fig"}), implying that: 1) affected subject 8404 would have carried the deletion, had DNA been available; and 2) the CNV is unlikely to be highly penetrant as it was observed in an unaffected adult relative. The structural variant was not detected in the remaining affected relatives and therefore did not segregate with disease status in this family ([Fig 2B](#pgen.1007535.g002){ref-type="fig"}).

![CNV deletion encompassing intron 1 of *CNTNAP2* in an extended family with bipolar disorder.\
A) CytoScan HD array output image shows the position of the drop in signal intensity of 340 probes, indicating a deletion spanning 131kb (chr7:146203548--146334635; GRCh37/hg19) found in the patient 8401. The position of the FOXP2 binding site within the deletion is shown above. B) The bipolar pedigree includes five patients with bipolar disorder I (BPI) across two generations. Symbols: \_, individuals with DNA available; &, individuals with whole exome data; \#, individuals analysed for genome-wide CNVs through the CytoScan HD array; blue squares, individuals included in CNV qPCR validation and genotyping analysis, for which heterozygous deletion carriers are indicated as "+/del" and non-carriers are indicated as "+/+". Inferred genotypes are in parentheses. C) Gene dosage results of the qPCR experiments validating the deletion in patient 8401, and showing the deletion in unaffected subject 8407.](pgen.1007535.g002){#pgen.1007535.g002}

Discussion {#sec009}
==========

During the last decade, the *CNTNAP2* gene has received considerable attention in the psychiatric genetics field, with a number of studies examining gene dosage, and common or rare variants associations across multiple major psychiatric disorders, which together provided compelling evidence that *CNTNAP2* may be a risk gene with pleiotropic effects in psychiatry. While homozygous mutations in this gene lead to a rare and severe condition described as CASPR2 deficiency disorder (CDD) \[[@pgen.1007535.ref007]\], characterized by profound intellectual disability, epilepsy, language impairment or regression \[[@pgen.1007535.ref007], [@pgen.1007535.ref008]\], heterozygous mutations or common variants have been suggested to be implicated in autism, whose clinical features overlap with some observed in CDD. *CNTNAP2* is categorised in the SFARI database as syndromic gene and one of the highest-ranking "strong candidate" gene for ASD ([https://gene.sfari.org](https://gene.sfari.org/)). Heterozygous deletions encompassing the *CNTNAP2* gene were described not only in autism but a wide range of phenotypes, including psychiatric or neurologic disorders, and language-related deficiencies. These structural variants were generally described as causative or highly penetrant \[[@pgen.1007535.ref013], [@pgen.1007535.ref029], [@pgen.1007535.ref031], [@pgen.1007535.ref055], [@pgen.1007535.ref057], [@pgen.1007535.ref059]\].

Examination of the distribution of all structural variants described thus far in psychiatric or neurologic patients showed comparable localisation to those found in the general population, suggesting that structural variants affecting *CNTNAP2* may be less relevant in disease susceptibility than previously considered. We were not able to directly compare frequencies of observed structural variants in cases versus controls due to reporting bias in case reports and a lack of information on how many cases were screened to identify those subjects with reportable *CNTNAP2* CNVs, which is a limitation of this study. In the ExAC database, *CNTNAP2* had fewer CNV variants than expected (11 observed vs. 16 expected, z = 0.43; [http://exac.broadinstitute.org](http://exac.broadinstitute.org/)), and its haploinsufficiency score of 0.59 is in the 8^th^ decile of all genes \[[@pgen.1007535.ref079]\], suggesting that *CNTNAP2* has a tendency to be intolerant to structural variants. A specific case-control CNV analysis is needed to examine CNV frequency differences, but would require a very large sample due to the rarity of CNVs at this locus. A close clinical psychiatric examination of the 66 parents with heterozygous deletions across *CNTNAP2* of CDD provides information on the prevalence of psychiatric conditions in individuals carrying *CNTNAP2* CNVs. All heterozygous family members carrying deletions or truncating mutations were described as phenotypically healthy, suggesting a lack of correlation between these deletions and any major psychiatric condition. Furthermore, parents who were carriers for heterozygous deletions in psychiatric/neurologic patients were described as unaffected at the time of reporting \[[@pgen.1007535.ref013], [@pgen.1007535.ref029], [@pgen.1007535.ref031], [@pgen.1007535.ref037], [@pgen.1007535.ref054], [@pgen.1007535.ref062]\], with two exception: one father of a proband with neonatal convulsion, and another father of an epileptic patient, were reported as affected \[[@pgen.1007535.ref056], [@pgen.1007535.ref059]\]. Moreover, discordant segregation for deletions in *CNTNAP2* was also observed in an ASD sib-pair \[[@pgen.1007535.ref013]\]. Several psychiatric patients who were reported to carry heterozygous structural variants in *CNTNAP2* were also described with translocations or other chromosomal abnormalities \[[@pgen.1007535.ref029], [@pgen.1007535.ref030], [@pgen.1007535.ref033], [@pgen.1007535.ref034], [@pgen.1007535.ref056], [@pgen.1007535.ref058], [@pgen.1007535.ref062]--[@pgen.1007535.ref065]\], therefore it is possible that these aberrations may explain the phenotype independently from the observed CNVs in *CNTNAP2*.

We also describe a new CNV deletion which does not segregate with disease in an extended family with bipolar disorder. This CNV removes the FOXP2 transcription factor binding site in intron 1 of *CNTNAP2*, and overlaps with structural variants described in a number of other psychiatric patients. This heterozygous deletion was identified in two individuals with bipolar I disorder from an extended family with five affected members, but was observed also in one unaffected relative (who underwent diagnostic interview at age \>40 and therefore was beyond the typical age of symptom onset). Hence, the deletion was not segregating with the disease and is unlikely to represent a highly penetrant risk variant in this family, although we cannot exclude a multiple hit model where the CNV deletion interacts with other etiologic risk variants at other loci to exert phenotypic effect.

*CNTNAP2*^*-/-*^ knock-out mice have been proposed as valid animal model for ASD considering the phenotypic similarities between ASD and the CASPR2 deficiency disorder \[[@pgen.1007535.ref002]\]. *CNTNAP2*^*-/-*^ knock-out mice showed abnormalities in the arborisation of dendrites, maturation of dendritic spines, defects in migration of cortical projection neurons, and reduction of GABAergic interneurons \[[@pgen.1007535.ref002], [@pgen.1007535.ref004]\]. Controversially, ASD is not a core feature in the most recent patient series reported with CASPR2 deficiency disorder \[[@pgen.1007535.ref007], [@pgen.1007535.ref008]\]. The association previously proposed around the relationship between heterozygous deletions in *CNTNAP2* and ASD does not have a support from mouse models, as heterozygous mice did not show any behavioural or neuropathological abnormalities that were observed in homozygous knockouts \[[@pgen.1007535.ref002]\]. Notwithstanding this, it is possible that the combination of heterozygous *CNTNAP2* deletions in a genomic background of increased risk (through inheritance of other common and rare risk variants at other loci) may lead to psychiatric, behavioural or neuropathological abnormalities.

Common variants in *CNTNAP2* are another class of genetic variation associated with several psychiatric or language-related phenotypes. The most interesting finding from studies of this variant class converge on markers rs7794745 and rs2710102, originally reported in ASD \[[@pgen.1007535.ref013], [@pgen.1007535.ref014]\], and replicated later in ASD or implicated in other phenotypes \[[@pgen.1007535.ref012], [@pgen.1007535.ref015], [@pgen.1007535.ref023], [@pgen.1007535.ref024], [@pgen.1007535.ref046]--[@pgen.1007535.ref048]\]. Neuroimaging studies have supported the notion that these common variants play a role in psychiatric disorders. SNP rs2710102 has been implicated in brain connectivity in healthy individuals \[[@pgen.1007535.ref016], [@pgen.1007535.ref018], [@pgen.1007535.ref019]\], and rs7794745 was implicated in audio-visual speech perception \[[@pgen.1007535.ref080]\], voice-specific brain function \[[@pgen.1007535.ref022]\], and was associated with reduced grey matter volume in left superior occipital gyrus \[[@pgen.1007535.ref020], [@pgen.1007535.ref021]\]. These studies focused principally on language tasks in general population, given the reported suggestive implications of *CNTNAP2* in language impairment traits of ASD or language-related phenotypes. However, the direct role of *CNTNAP2* in language is still unclear; indeed the language regression observed in patients with CASPR2 deficiency disorder are concomitant with seizure onset and may represent a secondary phenotypic effect caused by seizures \[[@pgen.1007535.ref007]\]. On the other hand, the first genetic association of rs7794745 and rs2710102 with ASD, as well as the other psychiatric diseases were based in studies with limited sample size, and recent studies failed to replicate associations between the two markers and ASD \[[@pgen.1007535.ref081], [@pgen.1007535.ref082]\]. Individual alleles associated in the past with limited numbers of patients warrant replications in adequately powered samples to ascertain *bona fide* findings considering the small size effects of common variants \[[@pgen.1007535.ref083]\], such as that attempted here. Using the largest case-control cohorts currently publicly available (PGC datasets), we did not find evidence for significant association of previously reported common variants, or a combined effect for common variants of *CNTNAP2* in the susceptibility of psychiatric disorders, nor did we find predicted functional SNPs with a role across disorders.

Finally, we examine evidence for rare variant contributions in *CNTNAP2*. Rare variants in the promoter or coding region were reported to play a role in the pathophysiology of ASD \[[@pgen.1007535.ref025], [@pgen.1007535.ref033]\], although a recent study including a large number of cases and controls did not find association of rare variants of *CNTNAP2* in ASD \[[@pgen.1007535.ref084]\]. Here we report the largest sample investigated thus far in ASD and schizophrenia, which suggests that rare variants in *CNTNAP2* do not play a major role in these two psychiatric disorders. Furthermore, examination of *de novo* variants in combined psychiatric sequencing projects of over 15,500 trios suggest that *de novo* variants in *CNTNAP2* do not increase risk for psychiatric disorders.

While functional studies show a relationship between certain deletions or rare variants of *CNTNAP2* with neuronal phenotypes relevant to psychiatric illness \[[@pgen.1007535.ref025], [@pgen.1007535.ref054], [@pgen.1007535.ref085]\], we show that the genetic link between these variants and psychiatric phenotypes is tenuous. However, this does not dispel the evidence that the *CNTNAP2* gene, or specific genetic variations within this gene, may have a real impact on neuronal functions or variability of brain connectivity in the general population.

It is now possible to combine large datasets to ascertain the real impact of candidate genes described in the past in psychiatric disorders. Here we performed analyses using large publicly available datasets investigating a range of mutational mechanisms which impact variability of *CNTNAP2* across several psychiatric disorders. In conclusion, our results converge to show a limited or likely neutral role of *CNTNAP2* in the susceptibility of psychiatric disorders. However, the impact of this gene in language deficit *per se* is not directly examined in this study and warrants additional investigation.

Methods {#sec010}
=======

Common variant association in *CNTNAP2* using publicly available datasets {#sec011}
-------------------------------------------------------------------------

We sought to replicate previously reported *CNTNAP2* SNP associations in a range of psychiatric phenotypes or traits using GWAS summary-statistic data of the Psychiatric Genomics Consortium (<https://med.unc.edu/pgc/results-and-downloads>).

Firstly, we report the corresponding *P-value*s of specific previously associated markers for case-control cohorts with autism spectrum disorder (ASD), schizophrenia (SCZ), bipolar disorder (BD), attention-deficit hyperactivity-disorder (ADHD), major depressive disorder (MDD), anorexia nervosa (AN), and obsessive compulsive disorder (OCD). If a specific SNP marker was not reported in an individual GWAS dataset, we selected another marker in high linkage disequilibrium (r^2^\~1, using genotype data from the CEU, TSI, GBR and IBS European populations in 1000genomes project; [http://www.internationalgenome.org](http://www.internationalgenome.org/)).

Next, a gene-based association for common variants was calculated with MAGMA \[[@pgen.1007535.ref086]\], using variants within a 5 kb window upstream and downstream of *CNTNAP2*. Selected datasets were of European descent, derived from GWAS summary statistics of the Psychiatric Genomics Consortium (<https://med.unc.edu/pgc/results-and-downloads>): SCZ (33,640 cases and 43,456 controls), BD (20,352 cases and 31,358 controls), ASD (6,197 and 7,377 controls), ADHD (19,099 cases and 34,194 controls), MDD (9,240 cases and 9,519 controls), OCD (2,688 cases and 7,037 controls), and AN (3,495 cases and 10,982 controls) \[[@pgen.1007535.ref087]--[@pgen.1007535.ref093]\]. Analyses were performed combining two different models for higher statistical power and sensitivity when the genetic architecture is unknown: the combined *P-value* model, which is more sensitive when only a small proportion of key SNPs in a gene show association; and the mean SNP association, which is more sensitive when allelic heterogeneity is greater and a larger number of SNPs show nominal association.

Finally, we selected SNPs predicted to be functional within a 5kb window upstream/downstream of *CNTNAP2* (e.g. located in transcription factor binding sites, miRNA binding sites etc; [https://snpinfo.niehs.nih.gov](https://snpinfo.niehs.nih.gov/)), and assessed a potential cross-disorder effect using GWAS summary statistics data of the PGC by performing a meta-analysis in PLINK \[[@pgen.1007535.ref094]\]. The Cochran's Q-statistic and I^2^ statistic were calculated to examine heterogeneity amongst studies. The null hypothesis was that all studies were measuring the same true effect, which would be rejected if heterogeneity exists across studies. For all functional SNPs, when heterogeneity between studies was I\>50% (*P*\<0.05), the pooled OR was estimated using a random-effects model.

Analysis of rare variants in *CNTNAP2* in ASD and schizophrenia, and *de novo* variants across psychiatric cohorts {#sec012}
------------------------------------------------------------------------------------------------------------------

The impact of rare variants of *CNTNAP2* was assessed using sequencing-level data from the following datasets: WES from the Sweden-Schizophrenia population-based Case-Control cohort (6,135 cases and 6,245 controls; dbGAP accession: phs000473.v2.p2); ARRA Autism Sequencing Collaboration (490 BCM cases, BCM 486 controls, and 1,288 unrelated ASD probands from consent code c1; dbGAP accession: phs000298.v3.p2); Medical Genome Reference Bank (2,845 healthy Australian adults; <https://sgc.garvan.org.au/initiatives/mgrb>); individuals from a Caucasian Spanish population (719 controls \[[@pgen.1007535.ref095], [@pgen.1007535.ref096]\]); in-house ASD patients (30 cases; \[[@pgen.1007535.ref097]\]); and previous published dataset in ASD (2,704 cases and 2,747 controls \[[@pgen.1007535.ref084]\]). The selection of potentially etiologic variants was performed based on their predicted pathogenicity (missense damaging in both SIFT and polyphen 2, canonical splice variants, stop mutation and indels) and minor allele frequency (MAF\<0.0001 in non-Finnish European populations using the Genome Aggregation Database; <http://gnomad.broadinstitute.org/>). A chi square statistic was used to compare separately the sample of schizophrenia patients (6,135 cases) and the combined ASD datasets (4,512 cases) with the combined control datasets (13,042 individuals).

Two databases for *de novo* variants were used to identify *de novo* variants in *CNTNAP2* \[[@pgen.1007535.ref098], [@pgen.1007535.ref099]\], which comprise data for the following samples: autism spectrum disorder (6,171 families), schizophrenia (1,164 families), epilepsy (647 families), intellectual disability (1,101 families), developmental disorders (4,293 families) and controls (2,163).

Extended family with bipolar disorder and CNV in *CNTNAP2* {#sec013}
----------------------------------------------------------

The extended family presented here ([Fig 2B](#pgen.1007535.g002){ref-type="fig"}) provides a molecular follow-up from a previously reported whole exome sequencing (WES) study of multiplex BD families, augmented with CNV microarray data \[[@pgen.1007535.ref078]\]. This multigenerational pedigree, was collected through the Mood Disorders Unit and Black Dog Institute at the Prince of Wales Hospital, Sydney, and the School of Psychiatry (University of New South Wales in Sydney) \[[@pgen.1007535.ref100]--[@pgen.1007535.ref104]\]. Consenting family members were assessed using the Family Interview for Genetic Studies (FIGS) \[[@pgen.1007535.ref105]\], and the Diagnostic Interview for Genetic Studies (DIGS) \[[@pgen.1007535.ref106]\]. The study was approved by the Human Research Ethics Committee of the University of New South Wales, and written informed consent was obtained from all participating individuals. Blood samples were collected for DNA extraction by standard laboratory methods. Three of the five relatives with bipolar disorder type I (BD-I) had DNA and WES-derived genotype data available, and six unaffected relatives with DNA and WES data were available for haplotype phasing and segregation analysis ([Fig 2B](#pgen.1007535.g002){ref-type="fig"}).

Genome-wide CNV analysis was performed via CytoScan HD Array (Affymetrix, Santa Clara, CA, USA) in 2 distal affected relatives (individuals 8410 and 8401; [Fig 2B](#pgen.1007535.g002){ref-type="fig"}), using the Affymetrix Chromosome Analysis Suite (ChAS) software (ThermoFisher, Waltham, MA, USA). Detailed information on CNV detection and filtering criteria have been previously described \[[@pgen.1007535.ref078]\]. We identified a 131kb deletion in intron 1 of *CNTNAP2* in individual 8401. WES-derived genotypes were used for haplotype assessment to infer CNV segregation amongst relatives, as previously described \[[@pgen.1007535.ref078]\]. Next, we experimentally validated the *CNTNAP2* CNV via quantitative PCR (qPCR) in all available family members. Validation was performed in quadruplicate via a SYBR Green-based quantitative PCR (qPCR) method using two independent amplicon probes, each compared with two different reference amplicon probes in the *FOXP2* and *RNF20* genes ([S4 Table](#pgen.1007535.s006){ref-type="supplementary-material"}). Experimental details are available upon request.
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###### Primers used in the CNV validation for the *CNTNAP2* intronic deletion.
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